Border to Coast Pensions Partnership Ltd Acquires 35,159 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Border to Coast Pensions Partnership Ltd increased its stake in Zimmer Biomet by 9.8%, purchasing 35,159 shares to hold 395,621 shares (about 0.20%) valued at roughly $35.64 million.
• Zimmer Biomet beat quarterly expectations with $2.42 EPS and revenue up 10.9% year-over-year, and the company set FY2026 guidance of 8.300–8.450 EPS.
• The company announced a quarterly dividend of $0.24 per share (annualized $0.96, ~1.0% yield) with an ex-dividend date of March 31 and payment on April 30, while institutional ownership remains high at about 88.9% as several large funds raised their positions.

Border to Coast Pensions Partnership Ltd lifted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 9.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 395,621 shares of the medical equipment provider's stock after purchasing an additional 35,159 shares during the period. Border to Coast Pensions Partnership Ltd owned about 0.20% of Zimmer Biomet worth $35,639,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. Dodge & Cox raised its stake in shares of Zimmer Biomet by 5.1% during the 3rd quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider's stock worth $2,286,793,000 after purchasing an additional 1,118,710 shares during the period. Capital International Investors raised its stake in shares of Zimmer Biomet by 11.5% during the 3rd quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider's stock worth $743,749,000 after purchasing an additional 778,467 shares during the period. Ameriprise Financial Inc. raised its stake in shares of Zimmer Biomet by 1.6% during the 3rd quarter. Ameriprise Financial Inc. now owns 3,789,200 shares of the medical equipment provider's stock worth $373,239,000 after purchasing an additional 58,335 shares during the period. Van ECK Associates Corp raised its stake in Zimmer Biomet by 2.4% in the 3rd quarter. Van ECK Associates Corp now owns 3,476,906 shares of the medical equipment provider's stock valued at $342,475,000 after acquiring an additional 82,375 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in Zimmer Biomet by 1.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,269,122 shares of the medical equipment provider's stock valued at $223,503,000 after acquiring an additional 39,146 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of the business's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the transaction, the senior vice president owned 10,224 shares of the company's stock, valued at approximately $967,803.84. The trade was a 20.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.28% of the company's stock.

Zimmer Biomet Stock Down 2.4%

Shares of NYSE ZBH opened at $94.19 on Thursday. Zimmer Biomet Holdings, Inc. has a 12 month low of $84.59 and a 12 month high of $108.29. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $18.23 billion, a price-to-earnings ratio of 26.61, a PEG ratio of 1.97 and a beta of 0.61. The business has a 50-day moving average of $93.44 and a 200-day moving average of $93.32.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The company had revenue of $2.24 billion during the quarter, compared to analyst estimates of $2.22 billion. During the same quarter in the previous year, the firm earned $2.31 earnings per share. Zimmer Biomet's revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet's payout ratio is presently 27.12%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ZBH shares. Weiss Ratings upgraded Zimmer Biomet from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Tuesday, April 7th. Wall Street Zen upgraded Zimmer Biomet from a "hold" rating to a "buy" rating in a research note on Saturday, April 11th. BTIG Research restated a "neutral" rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Evercore upgraded Zimmer Biomet from an "in-line" rating to an "outperform" rating and boosted their price objective for the company from $94.00 to $120.00 in a research note on Monday, January 5th. Finally, Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a research note on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $105.95.

Zimmer Biomet Company Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.